# Analysis of Strensiq Market Trends and Forecast Highlights Significant Long-Term Growth Potential - Published: 2026-11-12 - Author: [Healthcare News](https://healthcarenews.io/author/healthcarenews-io.md) - Topics: [News](https://healthcarenews.io/news.md) - Source: https://healthcarenews.io/news/analysis-of-strensiq-market-trends-and-forecast-highlights-significant-long-term-growth-po/ - Publication: Healthcare News - Publisher: Connectively (Terkel, Inc.) - Editorial policy: https://healthcarenews.io/editorial-policy/ [![The Business Research Company](https://www.einpresswire.com/image/medium/236757/tbrc.jpeg)](https://www.einpresswire.com/image/large/236757/tbrc.jpeg#1024x302) The Business Research Company [![Strensiq Market Overview](https://www.einpresswire.com/image/medium/1242582/strensiq-market-overview.jpeg)](https://www.einpresswire.com/image/large/1242582/strensiq-market-overview.png#1024x768) Strensiq Market Overview *The Business Research Company's Analysis of Strensiq Market Trends and Forecast Highlights Significant Long-Term Growth Potential* **Market expansion is supported by increasing adoption in adult-onset hpp patients, expansion of rare disease treatment access”** — The Business Research Company LONDON, GREATER LONDON, UNITED KINGDOM, November 12, 2026 /[EINPresswire.com](https://www.einpresswire.com/)/ -- "The pharmaceutical landscape for rare genetic conditions is witnessing notable advancements, particularly in therapies targeting hypophosphatasia. As awareness improves and new treatment options emerge, markets like Strensiq are gaining momentum. Let’s explore the current state of the [Strensiq market](https://www.thebusinessresearchcompany.com/purchaseoptions?id=20197&slug=strensiq-global-market-report), including its size, key growth drivers, emerging trends, and regional outlook. Understanding the [Strensiq Market Size](https://www.thebusinessresearchcompany.com/sample_request?id=20197&type=smp&name=Strensiq+Market+Report+2026) and Growth Potential The Strensiq market experienced steady expansion in the past due to better recognition of hypophosphatasia, incentives for orphan drugs, positive clinical evidence supporting enzyme replacement therapies, broader genetic testing programs, and heightened awareness among healthcare providers. Looking ahead, the market is expected to grow further fueled by increased adoption among adult-onset HPP patients, wider accessibility to treatments for rare diseases, rising investments in orphan drug development pipelines, a growing emphasis on home-based therapy administration, and ongoing progress in personalized treatment strategies. Key trends shaping this future include a stronger focus on enzyme replacement therapies, rising diagnosis rates of rare bone disorders, development of long-term treatment protocols, expanding use of subcutaneous delivery methods, and improved patient monitoring and adherence initiatives. Download a free sample of the [strensiq market report](https://www.thebusinessresearchcompany.com/report/strensiq-global-market-report): [https://thebusinessresearchcompany.com/sample\_request?id=12627444&type=smp&name=Strensiq%20Market%20Report%202026&utm\_source=EINPresswire&utm\_medium=Paid&utm\_campaign=Nov\_PR](https://thebusinessresearchcompany.com/sample_request?id=12627444&type=smp&name=Strensiq%20Market%20Report%202026&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Nov_PR) What Strensiq Is and How It Works Strensiq is a prescription medication that contains asfotase alfa, which serves as a targeted enzyme replacement therapy specifically developed for treating hypophosphatasia (HPP). This treatment is administered through subcutaneous injections multiple times per week and aims to replace the deficient enzyme in patients, thereby enhancing bone mineralization and supporting overall skeletal health. The Growing Importance of Rare Disease Treatment in the Strensiq Market Heightened attention on rare disease therapies is expected to be a significant driver behind the growth of the Strensiq market. Treatments for rare diseases focus on conditions affecting a small percentage of the population and often require specialized medications or therapies that are not widely available. This growing focus is driven by advances in precision medicine, unmet clinical needs, expanding regulatory incentives, and greater opportunities for innovation within healthcare. Strensiq plays a fundamental role in this space by replenishing the deficient alkaline phosphatase enzyme in hypophosphatasia patients, thus improving bone health, reducing skeletal deformities, and enhancing quality of life. For example, a report by the UK-based Cystic Fibrosis Trust in October 2024 highlighted that over 11,318 people were registered with cystic fibrosis in the UK during 2023, with 63.7% aged over 16 and 16.7% over 40, demonstrating the growing patient base benefiting from rare disease treatments like Strensiq. View the full strensiq market report: [https://thebusinessresearchcompany.com/report/strensiq-global-market-report?utm\_source=EINPresswire&utm\_medium=Paid&utm\_campaign=Nov\_PR](https://thebusinessresearchcompany.com/report/strensiq-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Nov_PR) Personalized Medicine as a Catalyst for Strensiq Market Growth The rise of personalized medicine is expected to further accelerate the Strensiq market. Personalized medicine tailors treatment and healthcare strategies to individual patient characteristics, including genetic profiles, lifestyle, and environmental factors. This approach improves therapy effectiveness while minimizing side effects. Strensiq supports personalized medicine by delivering targeted enzyme replacement therapy for hypophosphatasia patients, enabling customized treatment plans that address specific genetic mutations and disease severity. In February 2024, the US-based Personalized Medicine Coalition reported that the FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022, highlighting the growing adoption of tailored therapies that directly benefit markets like Strensiq. Impact of Increasing Healthcare Expenditures on the Strensiq Market The upward trend in healthcare spending is another important factor driving the Strensiq market forward. Healthcare expenditures cover all costs related to medical services, family planning, nutrition programs, and emergency health assistance. As more stakeholders prioritize advanced therapies and better patient outcomes, spending on specialized medical care continues to increase. Strensiq contributes to this rise by offering enzyme replacement therapy that improves outcomes for hypophosphatasia patients, creating demand for high-value treatments. For instance, in May 2023, the UK’s Office for National Statistics reported healthcare spending of approximately $362.08 billion (£292 billion) in 2023, marking a 5.6% nominal increase, although healthcare expenditures as a percentage of GDP slightly declined from 11.1% in 2022 to 10.9% in 2023. These trends highlight the growing financial commitment to innovative therapies, supporting the Strensiq market’s expansion. Regional Highlights and Future Outlook for the Strensiq Market In 2025, North America stood as the largest market for Strensiq, reflecting strong healthcare infrastructure and patient access. Meanwhile, the Asia-Pacific region is expected to register the fastest growth during the forecast period, driven by increasing awareness, expanding healthcare infrastructure, and rising incidences of rare diseases. The market report covers all key regions including Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, providing a thorough perspective on global market trends. New additions to our 2026 reports: • Market attractiveness scoring and analysis • Total addressable market (TAM) analysis • Company scoring matrix graphics and tables • Excel-based forecasting dashboards • Market hotspots infographics • Key technologies and future trend analysis • Updated graphics and tables Speak With Our Expert: Saumya Sahay Americas +1 310-496-7795 Asia +44 7882 955267 & +91 8897263534 Europe +44 7882 955267 Email: marketing@tbrc.info The Business Research Company - [www.thebusinessresearchcompany.com](http://www.thebusinessresearchcompany.com) Follow Us On: • LinkedIn: [https://in.linkedin.com/company/the-business-research-company](https://in.linkedin.com/company/the-business-research-company)" Oliver Guirdham The Business Research Company [+44 7882 955267]() [info@tbrc.info](mailto:info@tbrc.info) Visit us on social media: [LinkedIn](https://www.linkedin.com/company/the-business-research-company/) [Facebook](https://www.facebook.com/TheBusinessResearchCompany/) [X](https://twitter.com/tbrc_info) Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above. ![](https://www.einpresswire.com/tracking/article.gif?aid=954688979§ion=einpresswire&a=EKQUtPpShV3VfjBy&r=Ohkp76qG8AiWTQ6s&i=VhX3Z-e3FQgk0Wfc) ## Related - [Generic Nexletol and Nexlizet: a seventh drugmaker agrees to wait until 2040](https://healthcarenews.io/news/generic-nexletol-2040-seventh-settlement.md) - [Medicare counted 6,436 surgery centers in 2024. Trimedx now offers them equipment maintenance nationwide](https://healthcarenews.io/news/surgery-center-equipment-maintenance-trimedx-nationwide.md) - [Novartis again leads drugmakers on reaching patients in poorer countries in the 2026 Access to Medicine Index](https://healthcarenews.io/news/2026-access-to-medicine-index-novartis-ranks-first.md) - [Glanzmann thrombasthenia has no approved preventive treatment. A weekly injection enters its final-stage trial](https://healthcarenews.io/news/glanzmann-thrombasthenia-treatment-weekly-injection-phase-3.md)